Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation

Clin Infect Dis. 2016 Apr 1;62(7):951-3. doi: 10.1093/cid/ciw020. Epub 2016 Jan 19.

Authors

Rotraut Mössner¹, Nina Diering¹, Oliver Bader², Susann Forkel¹, Tobias Overbeck³, Uwe Gross², Bodo Grimbacher⁴, Michael P Schön¹, Timo Buhl¹

Affiliations

¹ Department of Dermatology, Venereology and Allergology.
² Institute of Medical Microbiology.
³ Department of Hematology and Oncology, University Medical Center Göttingen.
⁴ Center for Chronic Immunodeficiency, University Medical Center Freiburg, Germany Institute of Immunity and Transplantation, University College London, United Kingdom.

PMID: 26787170
DOI: 10.1093/cid/ciw020

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Candidiasis, Chronic Mucocutaneous / drug therapy*
Candidiasis, Chronic Mucocutaneous / immunology
Candidiasis, Chronic Mucocutaneous / pathology
Humans
Interleukin-17 / blood
Interleukin-17 / genetics*
Interleukin-17 / metabolism
Male
Mutation
Nitriles
Pyrazoles / therapeutic use*
Pyrimidines
STAT1 Transcription Factor / blood
STAT1 Transcription Factor / genetics*
STAT1 Transcription Factor / metabolism
Tongue / pathology

Substances

Interleukin-17
Nitriles
Pyrazoles
Pyrimidines
STAT1 Transcription Factor
STAT1 protein, human
ruxolitinib